Last reviewed · How we verify
Lactobacillus Crispatus M247
Lactobacillus crispatus M247 is a live biotherapeutic agent that restores and maintains a healthy vaginal microbiome by colonizing the vaginal tract with beneficial lactobacilli.
Lactobacillus crispatus M247 is a live biotherapeutic agent that restores and maintains a healthy vaginal microbiome by colonizing the vaginal tract with beneficial lactobacilli. Used for Bacterial vaginosis, Prevention of recurrent urogenital infections.
At a glance
| Generic name | Lactobacillus Crispatus M247 |
|---|---|
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Drug class | Live biotherapeutic product |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Women's Health |
| Phase | FDA-approved |
Mechanism of action
This probiotic strain works by establishing dominance of Lactobacillus crispatus in the vaginal microbiota, which produces lactic acid to maintain an acidic pH and inhibit pathogenic bacteria. By restoring eubiosis (healthy microbial balance), it reduces the risk of bacterial vaginosis, urogenital infections, and associated complications. The mechanism relies on competitive exclusion and antimicrobial metabolite production rather than systemic pharmacological activity.
Approved indications
- Bacterial vaginosis
- Prevention of recurrent urogenital infections
Common side effects
- Vulvovaginal irritation
- Vaginal discharge
- Vulvovaginal discomfort
Key clinical trials
- Study to Evaluate the Efficacy of Lactobacillus Crispatus M247 in the Prevention and Treatment of Recurrent Urinary Tract Infections (NA)
- Evaluation of the Efficacy and Safety of Lactobacillus Crispatus M247 (Crispact®) With Vaginal Laser Therapy in Menopausal Women With Atrophic Vulvovaginitis (VVA) (NA)
- Efficacy of Probiotic Lactobacillus Crispatus M247 in Promoting High-risk Human Papillomavirus (HR-HPV) Infection Clearance and Modifying Vaginal Microbiota (NA)
- Probiotc Lactobacillus Crispatus-M247 (Crispact®) Supplementation in the Sterilization of High-risk Human Papilloma (HPV-HR) Viruses (NA)
- Study to Investigate the Treatment Benefit of Probiotic Lactobacillus Crispatus M247 in Women Undergoing Homologous Level 2 Assisted Reproductive Technology (ART) Procedures (NA)
- "Lactobacillus Crispatus M247, LSIL and Microbiota" (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: